Abstract
The study of the entire genome provides for a complete and better understanding of functional relationship of different genes, genes coding for protein and other regulating sequences, as phenotypic expression is a complex interplay of these and much more. The genomic revolution, in its practically applicable form, is yet to arrive. This genomic sequence information for various organisms, including humans, is now influencing drug discovery which provides opportunity for researchers to develop new drugs/medicines. Major challenges in new drug discovery are to identify targets that are essential for the organism to survive. Several latest technologies have allowed us to understand the mechanisms of disease with respect to biological system concepts, and therefore therapeutic intervention has been developed using informative database and technologies. Therefore, with developing therapeutic interventions, it is imperative for pharmaceutical researchers to rethink about new drug discovery and targeting employing information obtained from the genomic revolution. The chapter is summarized with an outline on the brief introduction on genomic revolution followed by changing scenario in drug discovery and targeting and paradigm shift in the treatment of certain major conditions such as cancer, cardiovascular diseases and tuberculosis in postgenomic era.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bishop WE, Clarke DP, Travis CC (2001) The genomic revolution: what does it mean for risk assessment? Risk Anal 21(6):983–987
Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, Draetta GF, Fletcher CDM, Loda M (2012) Investigative pathology: leading the post-genomic revolution. Lab Investig 92:4–8
Collins F (2010) Has the revolution arrived? Nature 464:674–675
Dopazo J (2014) Genomics and transcriptomics in drug discovery. Drug Discov Today 19(2):126–132
Hartwell LH, Hopfield JJ, Leibler S, Murray AW (1999) From molecular to modular cell biology. Nature 402:C47–C52
Reuter JA, Spacek D, Snyder MP (2015) High-throughput sequencing technologies. Molecular Cell 58(4):586–597
Keim B (2010) 10 Years on, The genome revolution is only just beginning. http://wired.com/2010/03/genome-at-10/
Chivers T (2014) Genomics the revolution that’s transforming medicine. http://www.telegraph.co.uk/news/science/science-news/11309154/Genomics-the-revolution-that-transforming-medicine.html
Hofker MH, Wijmenga JFC (2014) The genome revolution and its role in understanding complex diseases. Biochim Biophys Acta 1842(10):1889–1895
Parkinson T (2002) The impact of genomics on anti-infectives drug discovery and development. Trends Microbiol 10(10):S22–S26
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715
Chiang SL, Mekalanos JJ, Holden DW (1999) In vivo genetic analysis of bacterial virulence. Annu Rev Microbiol 53:129–154
Capecchi B, Serruto D, AduBobie J, Rappuoli R, Pizza M (2004) The genome revolution in vaccine research. Curr Issues Mol Biol 6:17–28
Chanda SK, Caldwell JS (2003) Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today 8(4):168–174
Raczniak G, Ibba M, Söll D (2001) Genomics-based identification of targets in pathogenic bacteria for potential therapeutic and diagnostic use. Toxicology 160:181–189
Murphy MP (2000) Current pharmacogenomic approaches to drug development. Pharmacogenomics 1(2):115–123
Murphy MP (2000) Pharmacogenomics a new paradigm for drug development. Drug Discov World Fall 1:23–32
Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Pers Med 7(4):347–350
Roederer MW (2009) Cytochrome P450 enzymes and genotype-guided drug therapy. Curr Opin Mol Ther 11(6):632–640
Mok TS et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
Paez JG, Janne PA et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500
O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004
Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408–2417
Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580
Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58
Sawyers CL (2002) Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev 12(1):111–115
Singh SB, Lingham RB (2002) Current progress on farnesyl protein transferase inhibitors. Curr Opin Drug Discov Devel 5:225–244
Adjei A (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93(14):1062–1074
Stamenkovic I (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415–433
Ramnath N, Creaven PJ (2004) Matrix metalloproteinase inhibitors. Curr Oncol Rep 6:96–102
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff DJ (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. Clin Oncol 22:1430–1438
Zonnenberg BA, Groenewegen G, Janus TJ, Leahy TW, Humerickhouse RA, Isaacson JD, Car RA, Voest E (2003) Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 9:2965
Lee D (2003) Clinical trials of atrasentan in hormone-refractory prostate cancer. Clin Prostate Cancer 2(2):84–86
Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69(3):11–16
Singh SK, Vobbalareddy S, Shivaramakrishna S, Krishnamaraju A, Abdul Rajjak S, Casturi SR, Akhila V, Rao YK (2004) Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett 14:1683–1688
Zarghi A, Arfaei S (2011) Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res 10(4):655–683
Jhaveri K et al (2012) A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS- 1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res 18:5090–5098
National Cancer Institute (2014) Clinical trials search. http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12897579
Plump AS, Lum PY (2009) Genomics and cardiovascular drug development. J Am Coll Cardiol 53(13):1089–1100
Zycher B, DiMasi JA, Milne CP, The Truth about Drug Innovation (2008) Thirty-five summary case histories on private sector contributions to pharmaceutical science. Medical progress report. Manhattan Institute, New York
Scriabine A (2007) Challenges for cardiovascular drug research. Cardiovasc Drug Rev 259:205–220
Zadelaar S, Kleemann R, Verschuren L et al (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27:1706–1721
Reardon CA, Getz GS (2001) Mouse models of atherosclerosis. Curr Opin Lipidol 12:167–173
Ganesh SK et al (2013) Genetics and genomics for the prevention and treatment of cardiovascular disease: update a scientific statement from the American Heart Association. Circulation 24(31):1–39
Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, Herrington DM, Hong Y, Jaquish C, McDermott DA, O’Donnell CJ (2007) Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 115:2878–2901
Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA (2010) A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42:711–714
Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159:882–890
Zhou K et al (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43:117–120
Yee SW, Chen L, Giacomini KM (2012) The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet 44:359–360
Hirschhorn JN, Daly MJ (2005) Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6:95–108
Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, Shendure J (2011) Exome sequencing as a tool for mendelian disease gene discovery. Nat Rev Genet 12:745–755
McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN (2008) Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 9:356–369
Dewey FE, Pan S, Wheeler MT, Quake SR, Ashley EA (2012) DNA sequencing: clinical applications of new DNA sequencing technologies. Circulation 125:931–944
Chakravarti A, Kapoor A (2012) Genetics and genomics in cardiovascular gene discovery. In: Hill JA, Olson EN (eds) Muscle: fundamental biology and mechanism of disease. Elsevier, Waltham, pp 231–259
Mudd JO, Kass DA (2008) Tackling heart failure in the twenty-first century. Nature 451:919–928
Shah AM, Mann DL (2011) In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 378:704–712
Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH (2010) Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther 9:3137–3144
Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48
Ballell L et al (2013) Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem 8:313–321
Andries K et al (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707):223–227
Christophe T et al (2009) High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 5(10):e1000645
Pethe K et al (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19:1157–1160
Abrahams KA et al (2012) Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One 7:e52951
Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA (2005) Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56:968–974
Tahlan K et al (2012) SQ109 targets MmpL3, a membrane transporter of trehalosemonomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:1797–1809
Wilson R et al (2013) Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nat Chem Biol 9(8):499–506
Willand N et al (2009) Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 15:537–544
Bitter W et al (2009) Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog 5(10):e1000507
Simeone R, Bottai D, Brosch R (2009) ESX/type VII secretion systems and their role in host–pathogen interaction. Curr Opin Microbiol 12(1):4–10
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chejara, D.R. et al. (2018). Rethinking Drug Discovery and Targeting After the Genomic Revolution. In: Pathak, Y. (eds) Genomics-Driven Healthcare. Adis, Singapore. https://doi.org/10.1007/978-981-10-7506-3_1
Download citation
DOI: https://doi.org/10.1007/978-981-10-7506-3_1
Published:
Publisher Name: Adis, Singapore
Print ISBN: 978-981-10-7505-6
Online ISBN: 978-981-10-7506-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)